ELEVATE-TN
Six years on, most patients on acalabrutinib have still not progressed, and adding obinutuzumab also improved survival.
At 74.5 months median follow-up: median PFS not reached (either acalabrutinib arm) vs 27.8 months; OS significantly longer for acalabrutinib-obinutuzumab vs chemoimmunotherapy (HR 0.62); benefit in del(17p)/TP53 and unmutated IGHV. Lancet 2020; Blood 2025 (6-year).
- Median 27.8 months with Chlorambucil + obinutuzumab.
- Acalabrutinib + obinutuzumab: Median not reached.
- Acalabrutinib: Median not reached.
- "Not reached" means that, when the data were analysed, more than half of that group had not yet had the event, which is good news for that group.
- A median is a midpoint: half the people did better than this and half did worse.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- The treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Previously untreated CLL, age ≥65 or with comorbidities: acalabrutinib ± obinutuzumab vs chlorambucil + obinutuzumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
535 participants enrolled.
Median not reached · Median not reached
SourceNumbers not yet public.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (median, 6-year follow-up)primary | Acalabrutinib + obinutuzumab | 179 | Median not reached | — | — | link |
| Acalabrutinib | 179 | Median not reached | ||||
| Chlorambucil + obinutuzumab | 177 | 27.8 months | ||||
| Overall survival (A+O vs O+Clb) | Acalabrutinib + obinutuzumab | — | — | 0.62 | — | — |
| Chlorambucil + obinutuzumab | — | — |
Pages like this
not linked directly; found by shared links- TrialAMPLIFY
Shares Acalabrutinib, Obinutuzumab, BTK (Bruton tyrosine kinase), CD20.
- TrialBELLWAVE-011
Shares Acalabrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- Key paperAMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients
Shares Acalabrutinib, Obinutuzumab, BTK (Bruton tyrosine kinase), CD20.
- TrialGLOW
Shares Obinutuzumab, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- PairingVenetoclax + obinutuzumab (12 months)
Shares Obinutuzumab, CD20, Chronic lymphocytic leukaemia.
- TrialSEQUOIA
Shares ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TrialCELESTIAL-TNCLL
Shares Obinutuzumab, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TrialCLL13 / GAIA
Shares Obinutuzumab, BTK (Bruton tyrosine kinase), CD20, Chronic lymphocytic leukaemia.